Zentalis Pharmaceuticals ZNTL

$ 3.14 1.13%

Quarterly report 2024-Q3
added 11-12-2024

Zentalis Pharmaceuticals Balance Sheet 2011-2024 | ZNTL

Annual Balance Sheet Zentalis Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	17.7 M	4.26 M	-13.8 M	-	-81.6 M	-25.2 M	-	-	-	-	-	-	-
Long Term Debt	43.2 M	45.2 M	44.5 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.62 M	2.16 M	1.45 M	902 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	4.16 M	2.48 M	-	-	-	-	-	-	-
Total Current Liabilities	69.4 M	56.6 M	43.9 M	28.6 M	-	-	-	-	-	-	-	-	-
Total Liabilities	114 M	105 M	90 M	32.2 M	19.1 M	8.69 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-889 M	-596 M	-360 M	-201 M	-83 M	-37.3 M	-	-	-	-	-	-	-
Total Assets	552 M	539 M	455 M	366 M	103 M	41 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	28 M	43.1 M	59.7 M	55 M	67.2 M	25.2 M	-	-	-	-	-	-	-
Book Value	437 M	434 M	364 M	333 M	83.6 M	32.3 M	-	-	-	-	-	-	-
Total Shareholders Equity	437 M	434 M	364 M	333 M	-73.3 M	32.3 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Zentalis Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	40.5 M	41.3 M	42.6 M	43.2 M	43.3 M	44 M	44.8 M	45.2 M	43 M	45.1 M	45 M	44.5 M	-	-	-	1.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	96.3 M	109 M	98.7 M	114 M	104 M	98.2 M	104 M	105 M	100 M	95 M	90 M	90 M	41.1 M	36.4 M	35.7 M	32.2 M	32.2 M	32.2 M	32.2 M	19.1 M	19.1 M	19.1 M	19.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.01 B	-967 M	-878 M	-889 M	-828 M	-772 M	-660 M	-596 M	-541 M	-487 M	-419 M	-360 M	-310 M	-305 M	-251 M	-201 M	-201 M	-201 M	-201 M	-83 M	-83 M	-83 M	-83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	451 M	492 M	557 M	552 M	586 M	621 M	489 M	539 M	529 M	568 M	406 M	455 M	435 M	284 M	328 M	366 M	366 M	366 M	366 M	87.5 M	87.5 M	87.5 M	87.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	41.3 M	37 M	37.6 M	28 M	111 M	267 M	36.3 M	43.1 M	42.6 M	55.1 M	30.6 M	59.7 M	40.8 M	49.2 M	29 M	56.3 M	55 M	55 M	55 M	67.2 M	67.2 M	67.2 M	67.2 M	25.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	354 M	383 M	459 M	437 M	482 M	523 M	386 M	434 M	429 M	473 M	316 M	364 M	394 M	248 M	293 M	333 M	333 M	333 M	333 M	68.4 M	68.4 M	68.4 M	68.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	354 M	383 M	459 M	437 M	482 M	523 M	386 M	434 M	429 M	473 M	316 M	364 M	394 M	248 M	293 M	333 M	333 M	309 M	309 M	-73.3 M	-73.3 M	-73.3 M	-73.3 M	32.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency